Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOMIC: Magnesium Prophylaxis for NOAF in ICU
NCT05829317Phase 4Recruiting
- Start
- Aug 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of magnesium sulfate in Atrial fibrillation (AFib) (2 arms). Primary endpoint: RCT Feasibility at 90 days. Started Aug 2023; status: recruiting.
02
Drugs
magnesium sulfate
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05829317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829317.